Is the extent of lymphadenectomy a prognostic factor in International Federation of Gynecology and Obstetrics stage II endometrioid endometrial cancer?
- 10 January 2021
- journal article
- research article
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 47 (3) , 1134-1144
Abstract
Aim This study aimed to evaluate the prognostic significance of adequate lymph node dissection (LND) (≥10 pelvic lymph nodes (LNs) and ≥ 5 paraaortic LNs removed) in patients with International Federation of Gynecology and Obstetrics (FIGO) stage II endometrioid endometrial cancer (EEC). Methods A multicenter department database review was performed to identify patients who had been operated and diagnosed with stage II EEC at seven centers in Turkey retrospectively. Demographic, clinicopathological, and survival data were collected and analyzed. Results We identified 284 women with stage II EEC. There were 170 (59.9%) patients in the adequate lymph node dissection (LND) group and 114 (40.1%) in the inadequate LND group. The 5‐year overall survival (OS) rate of the inadequate LND group was significantly lower than that of the adequate LND group (84.1% vs. 89.1%, respectively; p = 0.028). In multivariate analysis, presence of lymphovascular space invasion (LVSI) (hazard ratio [HR]: 2.39, 95% confidence interval [CI]: 1.23–4.63; p = 0.009), age ≥ 60 (HR: 3.30, 95% CI: 1.65–6.57; p = 0.001], and absence of adjuvant therapy (HR: 2.74, 95% CI: 1.40–5.35; p = 0.003) remained as independent risk factors for decreased 5‐year disease‐free survival (DFS). Inadequate LND (HR: 2.34, 95% CI: 1.18–4.63; p < 0.001), age ≥ 60 (HR: 2.67, 95% CI: 1.25–5.72; p = 0.011), and absence of adjuvant therapy (HR: 4.95, 95% CI: 2.28–10.73; p < 0.001) were independent prognostic factors for decreased 5‐year OS in multivariate analysis. Conclusion Adequate LND and adjuvant therapy were significant for the improvement of outcomes in FIGO stage II EEC patients. Furthermore, LVSI was associated with worse 5‐year DFS rate in stage II EEC.Keywords
This publication has 34 references indexed in Scilit:
- Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratificationGynecologic Oncology, 2012
- Systematic Lymphadenectomy for Survival in Patients with Endometrial Cancer: A Meta-analysisJapanese Journal of Clinical Oncology, 2012
- Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised studyThe Lancet, 2009
- Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical TrialJNCI: Journal of the National Cancer Institute, 2008
- Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?American Journal of Obstetrics and Gynecology, 2008
- Carcinoma of the Corpus UteriInternational Journal of Gynecology & Obstetrics, 2006
- Therapeutic role of lymph node resection in endometrioid corpus cancerCancer, 2006
- Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patientsGynecologic Oncology, 2006
- A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group studyGynecologic Oncology, 2004
- Potential Therapeutic Role of Para-aortic Lymphadenectomy in Node-Positive Endometrial CancerGynecologic Oncology, 2000